Early responses of <i>EGFR</i> circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment

Fumio Imamura(Osaka International Cancer Institute), Kikuya Kato(Nara Institute of Science and Technology)

Oncotarget

September 30, 2016

10.18632/oncotarget.12373

Cited by 22

Related Papers

Monitoring gastric cancer progression with circulating tumour DNA

|British Journal of Cancer|2014|103

High-fidelity target sequencing of individual molecules identified using barcode sequences:<i>de novo</i>detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients

|DNA Research|2015|88

Analytical Performance of a Highly Sensitive System to Detect Gene Variants Using Next-Generation Sequencing for Lung Cancer Companion Diagnostics

|Diagnostics|2023|26

Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients

|Scientific Reports|2016|17

Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barcodes and a bioinformatic variant filter

|PLoS ONE|2018|17